{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:15:41Z","timestamp":1773328541241,"version":"3.50.1"},"reference-count":43,"publisher":"Japan Atherosclerosis Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2017]]},"DOI":"10.5551\/jat.32409","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T22:06:52Z","timestamp":1467929212000},"page":"157-168","source":"Crossref","is-referenced-by-count":8,"title":["Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin"],"prefix":"10.5551","volume":"24","author":[{"given":"Fumitaka","family":"Okajima","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Chiba-Hokusoh Hospital, Nippon Medical School"},{"name":"Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Emoto","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Chiba-Hokusoh Hospital, Nippon Medical School"},{"name":"Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhito","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chiba Hokusoh Hospital, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sugihara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986","DOI":"10.1056\/NEJM199309303291401"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N and Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28: 103-117","DOI":"10.1016\/0168-8227(95)01064-K"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC and Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321: 405-412","DOI":"10.1136\/bmj.321.7258.405"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N and Japan Diabetes Complications Study G. Serum triglyceride levels is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011; 96: 3448-3456","DOI":"10.1210\/jc.2011-0622"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Action to Control Cardiovascular Risk in Diabetes Study. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559","DOI":"10.1056\/NEJMoa0802743"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R and Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572","DOI":"10.1056\/NEJMoa0802987"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD and Investigators V. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-139","DOI":"10.1056\/NEJMoa0808431"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999; 354: 617-621","DOI":"10.1016\/S0140-6736(98)12131-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999; 22: 920-924","DOI":"10.2337\/diacare.22.6.920"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M and Group S-NTR. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290: 486-494","DOI":"10.1001\/jama.290.4.486"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D and Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: metaanalysis of seven long-term studies. Eur Heart J. 2004; 25: 10-16","DOI":"10.1016\/S0195-668X(03)00468-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tanimura K, Nakajima Y, Nagao M, Ishizaki A, Kano T, Harada T, Okajima F, Sudo M, Tamura H, Ishii S, Sugihara H, Yamashita S, Asai A and Oikawa S. Association of serum apolipoprotein B48 level with the presence of carotid plaque in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008; 81: 338-344","DOI":"10.1016\/j.diabres.2008.04.028"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nakano T, Nakajima K, Niimi M, Fujita MQ, Nakajima Y, Takeichi S, Kinoshita M, Matsushima T, Teramoto T and Tanaka A. Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases. Clin Chim Acta. 2008; 390: 38-43","DOI":"10.1016\/j.cca.2007.12.012"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Pal S, Semorine K, Watts GF and Mamo J. Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin Chem Lab Med. 2003; 41: 792-795","DOI":"10.1515\/CCLM.2003.120"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Masuda D, Sugimoto T, Tsujii K, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nishida M, Ishigami M, Kawamoto T, Matsuyama A, Sakai N, Komuro I and Yamashita S. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Invest. 2012; 42: 992-999","DOI":"10.1111\/j.1365-2362.2012.02687.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Mori K, Ishida T, Yasuda T, Monguchi T, Sasaki M, Kondo K, Hasokawa M, Nakajima H, Haraguchi Y, Sun L, Shinohara M, Toh R, Nishimura K and Hirata K. Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease. Clin Chim Acta. 2013; 421: 51-56","DOI":"10.1016\/j.cca.2013.02.005"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Masuda D, Sakai N, Sugimoto T, Kitazume-Taneike R, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M, Ishigami M, Masuda Y, Matsuyama A, Komuro I and Yamashita S. Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia. J Atheroscler Thromb. 2011; 18: 1062-1070","DOI":"10.5551\/jat.10470"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Sato I, Ishikawa Y, Ishimoto A, Katsura S, Toyokawa A, Hayashi F, Kawano S, Fujioka Y, Yamashita S and Kumagai S. Significance of measuring serum concentrations of remnant lipoproteins and apolipoprotein B-48 in fasting period. J Atheroscler Thromb. 2009; 16: 12-20","DOI":"10.5551\/jat.E596"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M and Komachi Y. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol. 2001; 153: 490-499","DOI":"10.1093\/aje\/153.5.490"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Bansal S, Buring JE, Rifai N, Mora S, Sacks FM and Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007; 298: 309-316","DOI":"10.1001\/jama.298.3.309"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Mora S, Rifai N, Buring JE and Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008; 118: 993-1001","DOI":"10.1161\/CIRCULATIONAHA.108.777334"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Haidari M, Leung N, Mahbub F, Uffelman KD, Kohen-Avramoglu R, Lewis GF and Adeli K. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem. 2002; 277: 31646-31655","DOI":"10.1074\/jbc.M200544200"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK and Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab. 2009; 94: 1843-1852","DOI":"10.1210\/jc.2008-1296"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. The Journal of clinical endocrinology and metabolism 2004; 89: 2078-2084","DOI":"10.1210\/jc.2003-031907"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26.Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes care 1994; 17: 1039-1044","DOI":"10.2337\/diacare.17.9.1039"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Xiao C, Bandsma RH, Dash S, Szeto L and Lewis GF. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol. 2012; 32: 1513-1519","DOI":"10.1161\/ATVBAHA.112.246207"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Wu Y, Yan P, Smith U, Yki-Jarvinen H, Diamant M and Taskinen MR. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis. 2010; 212: 223-229","DOI":"10.1016\/j.atherosclerosis.2010.04.024"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Eliasson B, Moller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P, Diamant M, Taskinen MR and Smith U. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and\/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012; 55: 915-925","DOI":"10.1007\/s00125-011-2447-3"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE and Taskinen MR. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006; 49: 2049-2057","DOI":"10.1007\/s00125-006-0340-2"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC and Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970; 19: 644-655","DOI":"10.2337\/diab.19.9.644"},{"key":"32","unstructured":"32) Schlichtkrull j MO and Jersild M. M-value, an index for blood sugar control in diabetics. Ugeskr Laeger. 1964; 126: 815-820"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Hanada H, Mugii S, Okubo M, Maeda I, Kuwayama K, Hidaka Y, Kitazume-Taneike R, Yamashita T, Kawase R, Nakaoka H, Inagaki M, Yuasa-Kawase M, Nakatani K, Tsubakio-Yamamoto K, Masuda D, Ohama T, Matsuyama A, Ishigami M, Nishida M, Komuro I and Yamashita S. Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism. Clin Chim Acta. 2012; 413: 160-165","DOI":"10.1016\/j.cca.2011.09.013"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Nakada Y, Kurosawa H, Tohyama J, Inoue Y and Ikewaki K. Increased remnant lipoprotein in patients with coronary artery disease--evaluation utilizing a newly developed remnant assay, remnant lipoproteins cholesterol homogenous assay (RemL-C). J Atheroscler Thromb. 2007; 14: 56-64","DOI":"10.5551\/jat.14.56"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Yoon NM, Cavaghan MK, Brunelle RL and Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 2009; 31: 1511-1523","DOI":"10.1016\/j.clinthera.2009.07.021"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Shimoda S, Iwashita S, Ichimori S, Matsuo Y, Goto R, Maeda T, Matsuo T, Sekigami T, Kawashima J, Kondo T, Matsumura T, Motoshima H, Furukawa N, Nishida K and Araki E. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocr J. 2013; 60: 1207-1214","DOI":"10.1507\/endocrj.EJ13-0198"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Schmidt WE, Siegel EG and Creutzfeldt W. Glucagonlike peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia. 1985; 28: 704-707","DOI":"10.1007\/BF00291980"},{"key":"38","unstructured":"38) Shah P, Vella A, Basu A, Basu R, Schwenk WF and Rizza RA. Lack of suppression of glucagon contributes to post prandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000; 85: 4053-4059"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Dunning BE and Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev. 2007; 28: 253-283","DOI":"10.1210\/er.2006-0026"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, King GL, Weir GC and Bonner-Weir S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes. 2007; 56: 1551-1558","DOI":"10.2337\/db06-1033"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014; 10: 711-722","DOI":"10.1038\/nrendo.2014.170"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Taskinen MR. Diabetic dyslipidemia. Atheroscler Suppl. 2002; 3: 47-51","DOI":"10.1016\/S1567-5688(01)00006-X"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Nakajima Y, Sato K, Sudo M, Nagao M, Kano T, Harada T, Ishizaki A, Tanimura K, Okajima F, Tamura H, Sugihara H, Tsuda K and Oikawa S. Practical dietary calorie management, body weight control and energy expenditure of diabetic patients in short-term hospitalization. J Atheroscler Thromb. 2010; 17: 558-567","DOI":"10.5551\/jat.3806"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/2\/24_32409\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:01:17Z","timestamp":1498327277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/2\/24_32409\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.32409","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}